To target Ras/CDK4/6-dependent pathways in MM, we examined Erk1/2i, CDK4/6i, and Erk1/2i + CDK4/6i treatment effects using in vitro and in vivo preclinical models of MM. This evidence concerns the gene CDK4 and Miyoshi myopathy.